Stage 1 breast cancer is highly curable. The 5-year relative survival rate for localized breast cancer is 100%, according to the National Cancer Institute’s SEER database. That statistic means people diagnosed at this stage survive at the same rate as the general population over five years. The vast majority of people treated for stage 1 breast cancer will never see their cancer return, though oncologists tend to use the term “no evidence of disease” rather than “cured” because a small residual risk of recurrence persists for years after treatment.
What “Curable” Actually Means in Oncology
Doctors rarely use the word “cured” when talking about cancer. The preferred terms are “remission” and “no evidence of disease” (NED), both meaning that no cancer is currently detectable through scans, bloodwork, or biopsies. The distinction matters: “cancer-free” implies that no residual cancer cells exist anywhere in the body and that the cancer will never return. That’s difficult to guarantee with certainty, since there is always at least a very slight risk of recurrence after a cancer diagnosis.
In practice, though, many doctors will declare a patient cancer-free after enough time has passed without a relapse. This typically coincides with the shift from active surveillance into survivorship, when checkups become less frequent. For stage 1 breast cancer, the prognosis is so favorable that the distinction between “cured” and “in remission” is largely academic for most patients.
What Stage 1 Means
Stage 1 breast cancer is divided into two subcategories based on tumor size and whether any cancer cells have reached nearby lymph nodes. In stage 1A, the tumor is no larger than 20 millimeters (about the size of a grape) and cancer has not spread to any lymph nodes. In stage 1B, either the tumor is 20 millimeters or smaller with tiny clusters of cancer cells (no larger than 2 millimeters) found in armpit lymph nodes, or there is no measurable tumor in the breast but those small lymph node deposits are present.
In both cases, the cancer is confined to the breast area. It has not spread to distant organs, which is the primary reason outcomes are so favorable.
How Breast Cancer Subtype Affects Outlook
Not all stage 1 breast cancers behave the same way. The biology of the tumor, specifically whether it is fueled by hormones, a protein called HER2, or neither, plays a significant role in both treatment decisions and recurrence risk.
The most common subtypes are hormone receptor-positive cancers, which tend to grow slowly and respond well to treatments that block estrogen. These carry the best prognosis at stage 1. Triple-negative breast cancer (TNBC), which lacks hormone receptors and HER2, is more aggressive even when caught early. A Mayo Clinic analysis of 602 patients with stage 1 TNBC found that the 5-year recurrence-free survival was 95 to 96% for those who received chemotherapy, compared to 85% for those treated with surgery alone. Tumor size mattered too: among patients who skipped chemotherapy, those with very small tumors (under 10 millimeters) had recurrence-free survival above 92%, while those with tumors between 10 and 20 millimeters dropped to 72%.
This is why your oncologist may recommend chemotherapy even for a small tumor if it turns out to be triple-negative. The subtype, not just the stage, shapes the treatment plan.
Surgery: Lumpectomy or Mastectomy
Most people with stage 1 breast cancer are candidates for breast-conserving surgery (lumpectomy), which removes the tumor and a margin of surrounding tissue while preserving the rest of the breast. Research comparing lumpectomy to mastectomy in early-stage patients has found no survival advantage for removing the entire breast. In fact, one large institutional analysis of stage 1 and 2 patients found that those who had lumpectomy had slightly better overall survival than those who had mastectomy, likely because lumpectomy patients also receive radiation, which provides an additional layer of protection.
Mastectomy remains the right choice in certain situations, such as when there are multiple tumor sites in the breast, when radiation isn’t feasible, or based on personal preference and genetic risk factors.
Radiation and When It Can Be Skipped
Radiation therapy after lumpectomy is standard because it significantly reduces the chance of cancer returning in the same breast. Treatment typically involves daily sessions over three to six weeks.
There is one notable exception. For women aged 70 or older with small, hormone receptor-positive, HER2-negative tumors and no lymph node involvement, research shows that hormone therapy alone after lumpectomy produces the same overall survival as radiation alone. A National Cancer Database analysis of this group found 5-year overall survival rates of 85% with hormone therapy and 86% with radiation, a difference that was not statistically significant. For older patients who want to avoid the time commitment and side effects of radiation, this is a reasonable and well-supported option.
Genomic Testing and Chemotherapy Decisions
One of the biggest questions for stage 1 patients with hormone receptor-positive cancer is whether they need chemotherapy on top of surgery and hormone therapy. Genomic tests analyze the activity of specific genes within the tumor to estimate recurrence risk and predict whether chemotherapy will help.
The most widely used test produces a recurrence score from 0 to 100. A score below 18 is considered low risk, meaning chemotherapy is likely to have little or no benefit beyond what hormone therapy already provides. A score of 31 or higher is considered high risk, and chemotherapy is recommended. Scores between 18 and 30 fall into an intermediate zone where the decision depends on additional factors like age. For many stage 1 patients with hormone-positive tumors, genomic testing confirms that chemotherapy can safely be skipped.
Hormone Therapy as Long-Term Protection
About two-thirds of breast cancers are hormone receptor-positive, meaning they grow in response to estrogen. For these cancers, hormone therapy after surgery is a cornerstone of treatment. The standard course is five years of daily oral medication that either blocks estrogen or suppresses its production.
For patients at higher risk of recurrence, extending hormone therapy beyond the initial five years offers additional protection. A meta-analysis of over 22,000 postmenopausal women found that an additional five years of treatment reduced the rate of recurrence by 27% and cut the risk of distant spread by roughly a quarter. The tradeoff is that hormone therapy can cause side effects like joint pain, hot flashes, and bone thinning, so the decision to extend treatment is weighed against quality of life.
The Reality of Long-Term Recurrence
While the short-term outlook for stage 1 breast cancer is excellent, breast cancer is unusual among cancers in that it can recur many years, even decades, after the original diagnosis. A study published in the Journal of the National Cancer Institute tracked patients beyond the 10-year mark and found a cumulative late recurrence rate of 8.5% at 15 years after diagnosis, 12.5% at 20 years, and 15.2% at 25 years. The risk does decline over time: the recurrence rate in years 10 to 12 was roughly double the rate seen after year 22.
These numbers include all early-stage patients and all subtypes, so individual risk varies. Hormone receptor-positive cancers account for most late recurrences, while triple-negative cancers that haven’t returned within the first five years are unlikely to come back later. This long tail of risk is the main reason oncologists hesitate to use the word “cured” and why ongoing monitoring matters.
What Follow-Up Looks Like
After completing treatment, you’ll transition into a surveillance schedule. Current guidelines recommend a physical exam and medical history review one to four times per year for the first five years, then annually after that. You’ll also have a mammogram every 12 months on any breast that wasn’t removed by mastectomy. Routine scans like CT or PET scans are not recommended for stage 1 survivors without symptoms, as they haven’t been shown to improve outcomes and can lead to unnecessary biopsies and anxiety.
The frequency of visits gradually decreases as the years pass, and for many people, follow-up eventually feels like a routine part of general health care rather than cancer monitoring.